57
Participants
Start Date
August 17, 2022
Primary Completion Date
June 23, 2025
Study Completion Date
June 23, 2025
GDC-1971
Capsule or tablet administered orally.
Atezolizumab
Administered as IV infusion.
Omeprazole
Administered orally as tablet or capsule in the acid-reducing agent assessment.
Auckland City Hospital, Auckland
St Vincent's Hospital Sydney, Darlinghurst
Austin Hospital, Heidelberg
Border Medical Oncology, Wodonga
Flinders Medical Centre, Bedford Park
One Clinical Research Perth, Nedlands
National Cancer Center, Goyang-si
Chungbuk National University Hospital, Cheongju-si
Sanatorio Allende, Córdoba
Fundacion CORI para la Investigacion y Prevencion del Cancer, La Rioja
Centro Medico IPAM, Rosario
Liga Paranaense de Combate Ao Cancer - Hospital Erasto Gaertner, Curitiba
Hospital de Clinicas de Porto Alegre HCPA PPDS, Pôrto Alegre
ONCOSITE Centro de Pesquisa Clínica Em Oncologia, Ijuí
Fundacao Pio XII Hospital de Cancer de Barretos, Barretos
Fundação Doutor Amaral Carvalho - Hospital Amaral, Jaú
Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto Hospital de Base - PPDS, São José do Rio Preto
Instituto do Cancer do Estado de Sao Paulo - ICESP, São Paulo
Instituto Brasileiro de Controle Do Câncer IBCC, São Paulo
Cross Cancer Institute, Edmonton
Ottawa Hospital, Ottawa
Princess Margaret Cancer Centre, Toronto
Seoul National University Hospital, Seoul
Severance Hospital, Yonsei University Health System, Seoul
Asan Medical Center - PPDS, Seoul
Lead Sponsor
Genentech, Inc.
INDUSTRY